Skip to content
Business

Bayer Wins FDA Approval for Sunharbo, the First Factor XIa Blood Thinner in the US

Bayer shares rose about 1.5% to their highest since May 2023 after the FDA approved Sunharbo, the first Factor XIa blood thinner in the US, which cut repeat strokes by 26% in its main trial.

A skybridge with the Bayer cross and the slogan 'Science For A Better Life' spans Sellerstrasse at Bayer's pharmaceuticals site in Berlin-Wedding.
Photo: Miriam Guterland / Wikimedia Commons, CC BY-SA 3.0

Bayer shares climbed about 1.5% shortly after the open on Tuesday to their highest level since May 2023, after the US Food and Drug Administration approved Sunharbo (asundexian), the first Factor XIa inhibitor approved in the US. In its main trial the once-daily pill cut repeat ischemic strokes by 26% with similar rates of major bleeding, and one analyst said the risk to Bayer's drug pipeline had fallen significantly.

The gain extends a strong run. Bayer was already the best performer in Germany's DAX this year, up about 55% since January, according to dpa-AFX. The shares closed last week at €55.58 after rising 15.01% in the week to 30 October and 9.89% in the week to 6 November, a two-week gain of about 26%.

Sunharbo in numbers

  • 26% fewer ischemic strokes in the OCEANIC-STROKE trial
  • 12,327 patients in the Phase III study
  • $748.50 US list price for a 30-day supply

What the FDA Approved

Bayer announced the decision late on Monday, US time. Sunharbo is a 50mg tablet taken once a day together with antiplatelet therapy. It is approved to reduce the risk of stroke in adults who have recently had a non-cardioembolic ischemic stroke, one not caused by a clot travelling from the heart, or a high-risk transient ischemic attack.

The FDA reviewed the application under Priority Review. China's regulator approved the drug in October, and applications in other markets are under review.

Bayer expects to start shipping in November, with hospitals and pharmacies able to order soon after. The list price is $748.50 for a 30-day supply, although Bayer says actual costs vary by health plan and coverage.

Bayer: share price, chart and news

Buildings of Bayer's pharmaceutical research centre on Aprather Weg in Wuppertal, Germany, seen from the road in May 2007.
Buildings of Bayer's pharmaceutical research centre on Aprather Weg in Wuppertal, Germany, seen from the road in May 2007. Photo: Atamari / Wikimedia Commons, CC BY-SA 3.0

The Trial Behind the Decision

The approval rests on OCEANIC-STROKE, a Phase III study that randomised 12,327 patients and was published in the New England Journal of Medicine. Adding asundexian to standard antiplatelet therapy cut ischemic strokes by 26% compared with antiplatelet therapy alone. TCTMD, a cardiology news service, reported an absolute reduction of 2.2 percentage points over two years of follow-up.

Major bleeding, the main concern with any blood thinner, ran at similar rates in both groups. Gastrointestinal bleeding ran at 2.7 events per 100 patient-years on asundexian against 2.1 on placebo. Some patients showed raised liver enzymes, about three quarters of those cases mild, according to Bayer.

The medical need is large. Bayer puts the number of strokes worldwide at about 12 million a year, and says roughly one in ten survivors of a non-cardioembolic ischemic stroke has another within a year.

Why Investors Care

Analysts treated the approval as a removal of risk rather than a surprise. Jefferies analyst Michael Leuchten, who rates the stock Neutral, said the US approval had been expected but that the risk to the pharma pipeline had fallen significantly. Bank of America kept its Buy rating and pointed to a good label, while Deutsche Bank Research raised its price target and kept a Buy rating.

dpa-AFX described the drug as the successor to Xarelto, Bayer's former blockbuster blood thinner, in stroke prevention. Replacing that income is central to the investment case for the pharmaceuticals division.

The approval arrives a week after Bayer lifted its 2026 guidance. On 3 November it raised its target for adjusted core earnings to €9.8bn to €10.3bn, from €9.6bn to €10.1bn, after third-quarter pharma sales of €4.68bn came in about 5% above analysts' forecasts in a Vara Research poll, Reuters reported. It also cut its expected net financial debt by €1bn, to €28bn to €29bn, and the shares rose about 5% that morning. Earlier, positive rulings in the US glyphosate litigation had already lifted the stock, dpa-AFX said.

What Comes Next

Uptake is the first test. Cheryl Bushnell of Wake Forest University School of Medicine told TCTMD that cost is likely to be the main limit on how widely the drug is used.

The second is the rest of the world, where Bayer's applications in other markets are still under review.

The third is the Roundup litigation. Bayer is waiting for a Missouri state court judge in St. Louis to rule on its proposed $7.25bn settlement of US claims over the weedkiller. Chief executive Bill Anderson said on 3 November that he expected approval before Christmas: "It could be any week now."

Sources

Related stories

Markets

Bayer Extends Its 15% Rally on a Roundup Jury Win and an Upgraded Outlook

Bayer shares rose about 5% after it raised its 2026 profit outlook on a strong pharma quarter, extending a 15% gain last week that followed a Roundup jury win. Q3 EBITDA beat…

Markets

Stellantis Leaps 15% and the DAX Gains 2.5% as Results Split Europe's Winners and Losers

The DAX rose 2.53% this week and the STOXX 600 1.73% as earnings split Europe. Stellantis jumped 15.38% in a day on a revenue beat; Adyen sank 13.35% after cutting its margin…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Markets

Bond Rout Drags Europe's Banks Lower as Infineon Surges 14% on the AI Chip Trade

The US 10-year yield hit 5.34%, its highest since 2002, and BNP Paribas fell 7.29% on the week as banks led Europe lower. Infineon rose 13.98%, with 8.78% on Friday alone, as money…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…